Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check4 days agoChange DetectedThe study page now lists related topics: Lung cancer and MedlinePlus Genetics. This improves access to disease- and genetics-related resources from the study record.SummaryDifference0.2%

- Check11 days agoChange DetectedThe related topics block including 'Lung cancer', 'related topics:', and 'MedlinePlus Genetics' is removed from the page, reducing quick-access consumer health links.SummaryDifference0.2%

- Check18 days agoChange DetectedAdded related topics sections for Lung cancer and MedlinePlus Genetics and updated the page revision tag to v3.6.6 (replacing v3.6.5). These changes affect metadata and navigation but do not modify the core study details or functionality.SummaryDifference0.2%

- Check25 days agoChange DetectedAn NIH grant/contract funding note was added to the study's identifiers, clarifying the funding source behind the trial. This addition provides funding transparency but does not alter study design, endpoints, or participant information.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision badge updated from v3.6.4 to v3.6.5, indicating a minor platform release. The update does not alter study details or visible content on the page.SummaryDifference0.0%

- Check54 days agoChange DetectedA new Revision: v3.6.4 tag was added and several unrelated topics/links along with an older Revision tag were removed, indicating a metadata cleanup rather than changes to the trial data.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.